Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10612studies shown

Showing 7,837-7,848 of 10,612

Drug study icon

TerminatedNCT03831113

Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionDrugFrom 18 Years to 45 Years

Countries: United States
Sponsor: Steve N. Caritis, MD
Condition: Addiction

Behavioral study icon

CompletedNCT00838981

Pharmacotherapy & CM for Opioid and Cocaine Dependence

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionBehavioralFrom 18 Years to 65 Years

Countries: United States
Sponsor: Yale University
Condition: Addiction

Behavioral study icon

CompletedNCT00000281

Pharmacotherapy for Schizophrenic Drug Users - 6

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionBehavioralFrom 18 Years to 55 Years

Countries: United States
Sponsor: Yale University
Condition: Addiction

Drug study icon

CompletedNCT00518947

Pharmacotherapy of Treatment-Resistant Mania

This summary needs review. Please check the official study record and contact the research team for details.

In United States

BipolarityDrugOver 18 Years

Countries: United States
Sponsor: University of Pittsburgh
Condition: Bipolarity

Behavioral study icon

CompletedNCT00469365

Pharmacy Interventions to Improve Chronic Disease Medication Refill

This summary needs review. Please check the official study record and contact the research team for details.

In United States

DepressionBehavioral

Countries: United States
Sponsor: Medical University of South Carolina
Condition: Depression

Drug study icon

CompletedNCT04987658

Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolarity type I

This study is completed in the United States. It is testing OLZ/SAM for Bipolarity.

In United States

BipolarityDrugFrom 10 Years to 12 Years

Countries: United States
Sponsor: Alkermes, Inc.
Condition: Bipolarity

Drug study icon

CompletedNCT02748694

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

This study is completed in the United States. It focuses on Schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Neurocrine Biosciences
Condition: Schizophrenia

Drug study icon

CompletedNCT05845398

Phase 1b Study of DCR-AUD in Healthy Volunteers

This summary needs review. Please check the official study record and contact the research team for details.

In United States

AddictionDrugFrom 21 Years to 65 Years

Countries: United States
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Condition: Addiction

Behavioral study icon

CompletedNCT02008396

Safety study of MDMA-assisted Therapy in anxiety

This study is completed in the United States. It is testing MDMA-assisted Therapy for anxiety.

In United States

AnxietyBehavioralOver 21 Years

Countries: United States
Sponsor: Resilient Pharmaceuticals
Condition: Anxiety

Drug study icon

CompletedNCT01642550

Study Safety and Efficacy of RM-131 Administered to Females With Eating disorders

This study is completed in the United States. It focuses on Eating disorders.

In United States

Eating disordersDrugFrom 18 Years to 45 Years

Countries: United States
Sponsor: Motus Therapeutics, Inc.
Condition: Eating disorders

Drug study icon

CompletedNCT05066672

NV-5138 for treatment-resistant depression

This study is completed in the United States. It is testing NV-5138 for treatment-resistant depression.

In United States

DepressionDrugFrom 18 Years to 70 Years

Countries: United States
Sponsor: Navitor Pharmaceuticals, Inc.
Condition: Depression

Drug study icon

CompletedNCT00100165

Phase 2 study of a Nicotinic Agonist in Schizophrenia

This study is completed in the United States. It is testing Phase 2 Trial of a Nicotinic Agonist for schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: University of Colorado, Denver
Condition: Schizophrenia

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.